Therapy Areas: Oncology
Resonant Therapeutics Forges Collaboration with Janssen
6 December 2019 - - US-based Resonant Therapeutics, Inc. has entered into an agreement with US-based healthcare company Johnson and Johnson's (NYSE: JNJ) Janssen Research and Development, LLC business with the aim to discover and validate novel tumor and immunological targets, and to validate certain therapeutic candidates, the company said.

The collaboration leverages Resonant's proprietary IMPaCT tumor microenvironment model and target validation platform, which earned them a Johnson and Johnson Innovation - JLABS @ TMC QuickFire Challenge award in 2016, and Janssen industry-leading oncology capabilities to rapidly advance new targets and therapeutic opportunities.

Specific details of the agreement were not disclosed.

Resonant exploits its proprietary IMPaCT tumor microenvironment model and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.

Its live cell, function-first approach lets the tumor cells, microenvironment, and live animal immune systems do the work of target and therapeutic candidate identification and validation.

Resonant's models are based in part on technology developed in the laboratory of Dr. Steve Weiss in the Life Sciences Institute at the University of Michigan in Ann Arbor.

The platform has undergone several years of optimisation, resulting in an industrialised process and the establishment of a broad pipeline of novel monoclonal antibody therapeutic candidates.

The company is a resident of Johnson and Johnson Innovation, JLABS, a life science incubator program. Resonant has received institutional funding from Mercury Fund (headquartered in Houston) and MINTS (Ann Arbor).
Login
Username:

Password: